NCT01022346已完成2 期
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Study of the Safety and Response Rate of 3 Subcutaneously Administered Doses of 5 X 10^7 PFU RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Grade 2 or 3 Associated With High Risk HPV Infection
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 206
- 主要终点
- Percentage of participants with CIN2/CIN3 associated with HPV16 single infection who achieved Histologic resolution (Defined as no CIN), determined by evaluation of tissue derived from surgical excision
研究概览
简要总结
This randomized, double-blind, placebo-controlled, parallel arm study will assess the safety and the efficacy of RO5217790 on histologic resolution in participants with high grade CIN associated with HR-HPV infection. Participants will be randomized to receive 3 subcutaneous injections of either placebo or RO5217790 on Days 1, 8, and 15. Study assessments will be made at Baseline, at Month 3 and 6, and every 6 months thereafter for an overall of 2.5 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Have a diagnosis within 2 months prior to the first dose of RO5217790 of CIN 2/3 confirmed by colposcopy-directed punch biopsy; patients must have at least 1 quadrant of residual CIN2/3 disease remaining after biopsy. Entry to the trial will be allowed based on the local assessment of this criterion; however, CIN 2/3 diagnosis will have to be confirmed by the central pathologist for the purposes of analyzing the study
- •Have satisfactory colposcopy, i.e. the entire acetowhite or disease area as well as the entire squamocolumnar junction visualized by colposcopy
- •Have detection at screening of a single or multiple HR-HPV infection by analysis of liquid based cytology (LBC) material on the Roche Linear Array assay consistent with any of the trial strata as specified in study protocol
排除标准
- •Have colposcopically visible CIN2/3 disease extending over more than 2 quadrants
- •Have any anatomical condition of the cervix, including that resulting from previous cervical surgery, congenital malformation or other condition, that would interfere with a complete evaluation of the transformation zone and surveillance of CIN. If an endocervical curettage (ECC) is performed, and the endocervical curettings reveal CIN, patients are eligible as long as the endocervical lesion is directly extending from the primary lesion and is colposcopically visible in its entirety
- •Have vulvar (VIN) or vaginal (VAIN) intraepithelial neoplasia
- •Have atypical endometrial or glandular cells or evidence of carcinoma on biopsy
- •Have a serious, concomitant disorder, including active systemic infection requiring treatment
- •Have a prior history of or current malignancy other than adequately treated skin cancer (squamous cell cancer or basal cell carcinoma), unless the history of skin cancer is at the site of study treatment administration
- •Have a proven or suspected immunosuppressive disorder or autoimmune disease
- •Have any significant cardiac, hepatic or renal disease
- •Have active viral infections including human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), cytomegalovirus (CMV), and Epstein barr virus (EBV) within 30 days of receiving study treatment. Mild viral infections such as Herpes Simplex Virus 1 (HSV-1) or common cold are not excluded
研究组 & 干预措施
Placebo
Placebo Comparator
Placebo matched to RO5217790 will be administered subcutaneously on Days 1, 8, and 15.
干预措施: Placebo (Drug)
RO5217790
Experimental
RO5217790 will be administered at a dose of 5*10^7 plaque forming unit (pfu) subcutaneously on Days 1, 8, and 15.
干预措施: RO5217790 (Drug)
结局指标
主要结局
Percentage of participants with CIN2/CIN3 associated with HPV16 single infection who achieved Histologic resolution (Defined as no CIN), determined by evaluation of tissue derived from surgical excision
时间窗: Month 6
次要结局
- Percentage of participants who achieved Histologic resolution (Defined as no CIN), determined by evaluation of tissue derived from surgical excision(Months 6)
- Percentage of participants with viral clearance based on Roche Linear assay results(Months 3 and 6)
- Percentage of participants who achieved Histologic response (Defined as CIN Grade less than [<] 2), determined by evaluation of tissue derived from surgical excision(Month 6)
- Percentage of participants with immunologic response to HPV antigens(Day 1 (predose), Days 8, 15, and 29, Months 3 and 6)
- Percentage of Participants with at least one Adverse Events (AEs)(Up to Month 30)
研究者
相似试验
已完成
3 期
A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular DiseaseDiabetes Mellitus Type 2NCT01018173Hoffmann-La Roche2,118
已完成
2 期
A Study of RO4917523 in Pediatric Patients With Fragile X SyndromeFragile X SyndromeNCT01750957Hoffmann-La Roche47
已完成
1 期
A Study of Aleglitazar in Combination With Aspirin in Healthy VolunteersHealthy VolunteerNCT01188304Hoffmann-La Roche44
已完成
1 期
A Study of Aleglitazar in Combination With Ibuprofen in Healthy VolunteersHealthy VolunteerNCT01188317Hoffmann-La Roche44
已完成
2 期
MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant TherapyMajor Depressive DisorderNCT01437657Hoffmann-La Roche319